Related Experiment Video

Updated: Jun 25, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Coronary artery restenosis: a paradigm of current treatment approaches

T J Kiernan1, G D Kiernan, B D Yan

  • 1Section of Vascular Medicine and Cardiology Intervention, Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. tjkiernan@partners.org

Minerva Cardioangiologica
|February 10, 2009
PubMed

Insights

Percutaneous coronary revascularization using angioplasty and stenting is standard for atherosclerotic disease. This review covers methods to treat and prevent neointimal hyperplasia, the cause of restenosis after these procedures.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Percutaneous coronary revascularization, including angioplasty and stenting, is a standard treatment for obstructive atherosclerotic vascular disease.
  • Neointimal formation is the primary pathological mechanism underlying restenosis following coronary angioplasty and stenting.

Purpose of the Study:

  • To review current therapeutic strategies for managing coronary artery restenosis.
  • To discuss preventative measures against neointimal hyperplasia after coronary interventions.

Main Methods:

  • Literature review of studies on coronary artery restenosis.
  • Analysis of pathological mechanisms of neointimal formation.
  • Evaluation of existing and emerging treatment modalities.

Main Results:

  • Neointimal hyperplasia remains a significant challenge after coronary stenting.
  • Various pharmacological and mechanical approaches are being investigated to mitigate restenosis.
  • Current strategies focus on inhibiting smooth muscle cell proliferation and migration.

Conclusions:

  • Effective management of coronary artery restenosis requires a comprehensive approach.
  • Further research is needed to optimize treatments for preventing and treating neointimal hyperplasia.
  • Advances in interventional cardiology aim to reduce long-term complications like restenosis.

More Related Videos

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...